Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Brent Kramer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18 years or more
Clinical diagnosis of blepharitis
Laboratory-confirmed fungal organisms from Part 1
Willingness to comply with QID (4 times a day) dosing for 21 days
For women of childbearing potential (WOCBP): willingness to use a highly effective method of contraception (combined hormonal contraception, progestogen-only hormonal contraception with ovulation inhibition, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomized partner, or sexual abstinence) from at least 14 days prior to first dose of Natacyn through 30 days after the last dose. WOCBP is defined as a woman who has experienced menarche and is not surgically sterile or postmenopausal (defined as 12 or more consecutive months of amenorrhea).
Ability to provide informed consent
You may not be if
Antifungal therapy within 3 months
Hypersensitivity to natamycin
Active keratitis or severe ocular infection
Pregnancy or breastfeeding
Participation in another interventional ocular study
Clareo Health | Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study
